Physician profile
Chase E Newby
NPI 1639825060
$6,318.18
in general payments reported to CMS, 2019-2025
28 companies · $3,753 in 2025
The $3,753 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.93 · 2023: $540 · 2024: $1,933 · 2025: $3,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,729 · Travel and Lodging: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,728.96 |
| Travel and Lodging | $1,496.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,208.98 | 2023-2025 | Corevalve Evolut R, Linq II, Micra |
| Pfizer INC. | $518.88 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $394.86 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $329.50 | 2023-2025 | Verquvo |
| Abiomed | $271.51 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $220.26 | 2024-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $158.28 | 2024-2025 | Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.10 | 2022-2025 | Jardiance |
| Heartflow, INC. | $154.42 | 2025 | |
| Novo Nordisk INC | $107.35 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $102.44 | 2024-2025 | Watchman Flx, Vigilant X4 Crt-D |
| Amgen INC. | $101.07 | 2023-2025 | Repatha, Repatha |
| Bridgebio Pharma, INC. | $87.40 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.93 | 2023-2024 | Lifevest |
| Edwards Lifesciences Corporation | $62.18 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $61.68 | 2025 | Onpattro, Amvuttra |
| Itamar Medical INC | $50.86 | 2024 | Watchpatone |
| Scpharmaceuticals INC. | $39.50 | 2024 | |
| Atricure, INC. | $38.55 | 2024 | |
| Impulse Dynamics (USA) INC. | $33.88 | 2025 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $26.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.05 | 2024 | Xarelto |
| Baxter Healthcare | $21.70 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2022 | |
| Irhythm Technologies, INC. | $15.18 | 2024 | Zio Monitor, Zio Xt Patch |
| Biotronik INC. | $14.67 | 2024 | Biomonitor |
| Esperion Therapeutics, INC. | $14.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Newby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.